A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Most protocols involve Retatrutide dosed weekly and Sermorelin administered nightly before bed
Tirzepatide microdosing uses low doses, up to 3 mg weekly, in a structured and supervised program
This means it only triggers insulin release when blood sugar is elevated, reducing the risk of hypoglycemia
PubMed Pratley RE, et al
Furthermore, regarding the mechanisms of GLP-1 secretion regulation in intestinal L-cells, including the potentiation mechanism of the main pathway, many unresolved aspects remain to be elucidated
